Lanvis

Lanvis Adverse Reactions

tioguanine

Manufacturer:

Aspen

Distributor:

Zuellig Pharma
Full Prescribing Info
Adverse Reactions
For this product there is a lack of modern clinical documentation which can be used as support for determining the frequency of undesirable effects. LANVIS is usually one component of combination chemotherapy and consequently it is not possible to ascribe the side effects unequivocally to this drug alone.
The following convention has been utilised for the classification of frequency of undesirable effects: very common ≥1/10 (≥10%), common ≥1/100 and < 1/10 (≥ 1% and <10%), uncommon ≥1/1000 and <1/100 (≥0.1% and <1%), rare ≥1/10,000 and <1/1000 (≥0.01% and <0.1%), very rare <1/10.000 (<0.01%). (See table.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: Hepatobiliary disorders: The liver toxicity associated with vascular endothelial damage occurs at a frequency of very common when thioguanine is used in maintenance or similar long term continuous therapy which is not recommended (see Dosage & Administration and Precautions).
Rare: Centrilobular hepatic necrosis has been reported in a few cases including patients receiving combination chemotherapy, oral contraceptives, high dose thioguanine and alcohol.
Reversal of signs and symptoms of this liver toxicity has been reported upon withdrawal of short term or long term continuous therapy.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in